Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
Niranjan Awasthi; Changhua Zhang; Anna M. Schwarz; Stefan Hinz; Changguang Wang; Noelle S. Williams; Margaret A. Schwarz; Roderich E. Schwarz(Profiled Authors: Margaret Schwarz; Roderich E Schwarz; Noelle S Williams)
Gemcitabine has limited clinical benefits in pancreatic ductal adenocarcinoma. The solvent-based traditional taxanes docetaxel and paclitaxel have not shown clinical results superior to gemcitabine. Nab-paclitaxel, a water-soluble albumin-bound paclitaxel, may carry superior distribution properties into the tumor microenvironment and has shown efficacy in multiple tumor types. We evaluated nab-paclitaxel effects compared with gemcitabine or docetaxel. For pancreatic ductal adenocarcinoma cells AsPC-1, BxPC-3, MIA PaCa-2 and Panc-1, gemcitabine IC50 ranged from 494 nM to 23.9μM; docetaxel IC
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Niranjan Awasthi; Amanda Kirane; Margaret A. Schwarz; Jason E. Toombs; Rolf A. Brekken; Roderich E. SchwarzBMC Cancer. 2011;11.
Niranjan Awasthi; Margaret A. Schwarz; Roderich E. SchwarzHPB. 2011;13(9):597-604.
Niranjan Awasthi; Changhua Zhang; Winston Ruan; Margaret A. Schwarz; Roderich E. SchwarzPLoS ONE. 2012;7(6).
Appears in this Document